Display options
Cite
Sabo AA, Birolo G, Naccarati A, et al. Small Non-Coding RNA Profiling in Plasma Extracellular Vesicles of Bladder Cancer Patients by Next-Generation Sequencing: Expression Levels of miR-126-3p and piR-5936 Increase with Higher Histologic Grades. Cancers (Basel). 2020;12(6)doi: 10.3390/cancers12061507.
Sabo, A. A., Birolo, G., Naccarati, A., Dragomir, M. P., Aneli, S., Allione, A., Oderda, M., Allasia, M., Gontero, P., Sacerdote, C., Vineis, P., Matullo, G., & Pardini, B. (2020). Small Non-Coding RNA Profiling in Plasma Extracellular Vesicles of Bladder Cancer Patients by Next-Generation Sequencing: Expression Levels of miR-126-3p and piR-5936 Increase with Higher Histologic Grades. Cancers, 12(6), . https://doi.org/10.3390/cancers12061507
Sabo, Alexandru A, et al. "Small Non-Coding RNA Profiling in Plasma Extracellular Vesicles of Bladder Cancer Patients by Next-Generation Sequencing: Expression Levels of miR-126-3p and piR-5936 Increase with Higher Histologic Grades." Cancers vol. 12,6 (2020). doi: https://doi.org/10.3390/cancers12061507
Sabo AA, Birolo G, Naccarati A, Dragomir MP, Aneli S, Allione A, Oderda M, Allasia M, Gontero P, Sacerdote C, Vineis P, Matullo G, Pardini B. Small Non-Coding RNA Profiling in Plasma Extracellular Vesicles of Bladder Cancer Patients by Next-Generation Sequencing: Expression Levels of miR-126-3p and piR-5936 Increase with Higher Histologic Grades. Cancers (Basel). 2020 Jun 09;12(6). doi: 10.3390/cancers12061507. PMID: 32527011; PMCID: PMC7352804.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2020 Jun 09;12(6). doi: 10.3390/cancers12061507.

Small Non-Coding RNA Profiling in Plasma Extracellular Vesicles of Bladder Cancer Patients by Next-Generation Sequencing: Expression Levels of miR-126-3p and piR-5936 Increase with Higher Histologic Grades.

Cancers

Alexandru A Sabo, Giovanni Birolo, Alessio Naccarati, Mihnea P Dragomir, Serena Aneli, Alessandra Allione, Marco Oderda, Marco Allasia, Paolo Gontero, Carlotta Sacerdote, Paolo Vineis, Giuseppe Matullo, Barbara Pardini

Affiliations

  1. Klinikum Stuttgart, Olgahospital, Zentrum für Kinder, Jugend und Frauenmedizin, Pediatrics 2 (General and Special Pediatrics), 70174 Stuttgart, Germany.
  2. Department of Pediatrics, Marie Curie Emergency Clinical Hospital for Children, 041434 Bucharest, Romania.
  3. Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
  4. Italian Institute for Genomic Medicine (IIGM) 10060 Candiolo, Italy.
  5. Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
  6. Department of Surgery, Fundeni Clinical Hospital, Carol Davila University of Medicine and Pharmacy, 022328 Bucharest, Romania.
  7. Department of Surgical Sciences, University of Turin and Città della Salute e della Scienza, 10126 Turin, Italy.
  8. Center for Cancer Prevention (CPO-Piemonte), 10126 Turin, Italy.
  9. MRC-HPA Centre for Environment and Health, School of Public Health, Imperial College London, London W2 1PG, UK.

PMID: 32527011 PMCID: PMC7352804 DOI: 10.3390/cancers12061507

Abstract

Bladder cancer (BC) is the tenth most frequent cancer worldwide. Due to the need for recurrent cystoscopies and the lack of non-invasive biomarkers, BC is associated with a high management burden. In this respect, small non-coding RNAs (sncRNAs) have been investigated in urine as possible biomarkers for BC, but in plasma their potential has not yet been defined. The expression levels of sncRNAs contained in plasma extracellular vesicles (EVs) from 47 men with BC and 46 healthy controls were assessed by next-generation sequencing. The sncRNA profiles were compared with urinary profiles from the same subjects. miR-4508 resulted downregulated in plasma EVs of muscle-invasive BC patients, compared to controls (adj-

Keywords: bladder cancer; extracellular vesicles; liquid biopsy; microRNAs; next-generation sequencing; non-invasive biomarkers; piRNAs; small non-coding RNA profiling

References

  1. Urol Oncol. 2019 Apr;37(4):292.e19-292.e27 - PubMed
  2. Int J Mol Sci. 2020 Mar 11;21(6): - PubMed
  3. Oncotarget. 2017 Apr 11;8(15):24668-24678 - PubMed
  4. BMC Bioinformatics. 2013 Apr 15;14:128 - PubMed
  5. Cancers (Basel). 2019 Aug 14;11(8): - PubMed
  6. Oncotarget. 2017 Dec 14;9(3):3097-3111 - PubMed
  7. Oncol Rep. 2014 Apr;31(4):1832-8 - PubMed
  8. Nat Rev Genet. 2019 Feb;20(2):89-108 - PubMed
  9. Brief Funct Genomic Proteomic. 2009 May;8(3):174-83 - PubMed
  10. J Cancer Res Clin Oncol. 2019 Nov;145(11):2725-2736 - PubMed
  11. Eur J Pharm Sci. 2017 Feb 15;98:70-79 - PubMed
  12. Eur Urol Focus. 2019 May;5(3):457-466 - PubMed
  13. Front Oncol. 2018 Sep 07;8:362 - PubMed
  14. Oncotarget. 2018 Apr 17;9(29):20658-20669 - PubMed
  15. Sci Rep. 2017 Nov 10;7(1):15277 - PubMed
  16. DNA Cell Biol. 2016 May;35(5):249-56 - PubMed
  17. Cancer Treat Rev. 2018 May;66:56-63 - PubMed
  18. Urology. 2003 Jan;61(1):109-18; discussion 118 - PubMed
  19. Stem Cells. 2016 May;34(5):1297-309 - PubMed
  20. Transl Androl Urol. 2019 Feb;8(1):5-11 - PubMed
  21. Mol Ther. 2016 Oct;24(10):1823-1835 - PubMed
  22. Urol Oncol. 2010 Nov-Dec;28(6):655-61 - PubMed
  23. Prostate. 2018 May;78(6):411-418 - PubMed
  24. Gene. 2018 Apr 15;650:60-67 - PubMed
  25. Biomark Med. 2018 Jun;12(6):667-676 - PubMed
  26. Am J Cancer Res. 2018 Sep 01;8(9):1674-1688 - PubMed
  27. Am J Transl Res. 2015 Nov 15;7(11):2500-9 - PubMed
  28. Genome Biol. 2014;15(12):550 - PubMed
  29. Onco Targets Ther. 2017 May 22;10:2665-2673 - PubMed
  30. Nat Rev Clin Oncol. 2018 Sep;15(9):541-563 - PubMed
  31. Oncotarget. 2016 Sep 20;7(38):61312-61324 - PubMed
  32. J Extracell Vesicles. 2014 Mar 26;3: - PubMed
  33. Eur Urol. 2017 Jan;71(1):96-108 - PubMed
  34. Biomed Res Int. 2013;2013:253957 - PubMed
  35. J Urol. 2012 Aug;188(2):615-23 - PubMed
  36. Cancers (Basel). 2019 Mar 17;11(3): - PubMed
  37. Isr Med Assoc J. 2004 Aug;6(8):474-8 - PubMed
  38. Nat Rev Urol. 2020 Jan;17(1):11-27 - PubMed
  39. ScientificWorldJournal. 2010 Oct 12;10:2090-100 - PubMed
  40. Int J Cancer. 2013 Oct 15;133(8):2004-9 - PubMed
  41. Gene. 2018 Nov 15;676:298-305 - PubMed
  42. Radiat Oncol. 2012 Nov 20;7:195 - PubMed
  43. PLoS One. 2018 Oct 18;13(10):e0206239 - PubMed
  44. Bioinformatics. 2012 Jul 15;28(14):1838-44 - PubMed
  45. Cell. 2018 Aug 9;174(4):1038-1038.e1 - PubMed
  46. Mol Carcinog. 2016 Nov;55(11):1833-1842 - PubMed
  47. Oncol Lett. 2018 May;15(5):8157-8164 - PubMed
  48. Mol Cancer. 2015 Nov 14;14:194 - PubMed
  49. Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7 - PubMed
  50. Cancer Sci. 2019 Jan;110(1):408-419 - PubMed
  51. Oncol Rep. 2016 Oct;36(4):2421-9 - PubMed
  52. BJU Int. 2014 Mar;113(3):437-48 - PubMed
  53. CA Cancer J Clin. 2018 Nov;68(6):394-424 - PubMed
  54. Int J Cancer. 2016 May 15;138(10):2334-45 - PubMed
  55. Expert Rev Mol Diagn. 2020 Feb;20(2):151-167 - PubMed

Publication Types

Grant support